ViAqua

Rehovot, Israel Founded: 2014 • Age: 12 yrs
RNAi drug delivery technology is developed for aquaculture disease prevention.
Request Access

About ViAqua

ViAqua is a company based in Rehovot (Israel) founded in 2014 by Shai Ufaz and Shai Einbinder.. ViAqua has raised $12.55 million across 5 funding rounds from investors including Nutreco, The Trendlines Group and Thai Union Group. ViAqua offers products and services including RNAi Delivery Platform. ViAqua operates in a competitive market with competitors including Sirnaomics, Arcturus Therapeutics, Vaxxas, Topas Therapeutics and Ensysce, among others.

  • Headquarter Rehovot, Israel
  • Founders Shai Ufaz, Shai Einbinder
  • Sectors
    Technology
    Agriculture
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Viaqua Therapeutics Ltd
Operational Areas
Technology → Quantum & Emerging Technologies
Agriculture → Aquaculture & Fisheries
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $12.55 M (USD)

    in 5 rounds

  • Latest Funding Round
    $8.25 M (USD), Series A

    Sep 05, 2023

  • Investors
    Nutreco

    & 8 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ViAqua

ViAqua offers a comprehensive portfolio of products and services, including RNAi Delivery Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Encapsulated RNA in feed for preventing viral diseases in shrimp.

People of ViAqua
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 1
Employee Profiles
People
Chris Beattie
Active Director
People
Shai Ufaz
CEO & Co-Founder
People
Shai Einbinder
Co-Founder
People
Ami Schlesinger
EVP, Business Development

Unlock access to complete

Board Members and Advisors
people
Avi Schroeder
Scientific Advisor

Unlock access to complete

Funding Insights of ViAqua

ViAqua has successfully raised a total of $12.55M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $8.25 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series A — $8.2M
  • First Round
  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2023 Amount Series A - ViAqua Valuation S2G Ventures
Jun, 2021 Amount Series A - ViAqua Valuation S2G Ventures
Dec, 2018 Amount Series A - ViAqua Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ViAqua

ViAqua has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Nutreco, The Trendlines Group and Thai Union Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Stage agnostic venture capital firm
Founded Year Domain Location
-
Founded Year Domain Location
Venture capital fund and startup incubator for healthcare and agricultural companies
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ViAqua

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ViAqua

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Viaqua Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ViAqua

ViAqua operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Arcturus Therapeutics, Vaxxas, Topas Therapeutics and Ensysce, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
RNA-based therapeutics for cancer and fibrosis are developed.
domain founded_year HQ Location
RNAi technologies are developed for treating rare orphan diseases.
domain founded_year HQ Location
Developer of vaccines to treat cancer and infectious diseases
domain founded_year HQ Location
Nanoparticle-based therapeutics for immunology disorders are developed.
domain founded_year HQ Location
Drug delivery solutions via single-walled carbon nanotubes are offered.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Viaqua

Frequently Asked Questions about ViAqua

When was ViAqua founded?

ViAqua was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is ViAqua located?

ViAqua is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.

Who is the current CEO of ViAqua?

Shai Ufaz is the current CEO of ViAqua. They have also founded this company.

Is ViAqua a funded company?

ViAqua is a funded company, having raised a total of $12.55M across 5 funding rounds to date.

What does ViAqua do?

ViAqua was founded in 2014 in Rehovot, Israel, focusing on the aquaculture sector. RNAi nanoparticle formulations are developed as a drug delivery platform for oral or immersion administration. Treatments are designed to halt disease progression and prevent viral outbreaks in aquatic species. Cellular responses are triggered by the technology to neutralize infections, with delivery occurring through feed integration or direct immersion methods.

Who are the top competitors of ViAqua?

ViAqua's top competitors include Sirnaomics, Arcturus Therapeutics and Splice Bio.

What products or services does ViAqua offer?

ViAqua offers RNAi Delivery Platform.

Who are ViAqua's investors?
Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available